The peptidomimetic, 1-adamantyl-substituted, and flex-het classes of retinoid-derived molecules: Their structure-activity relationships and retinoid receptor-independent anticancer activities

Mini-Reviews in Medicinal Chemistry

Volumn 10, Issue 6, 2010, Pages 455-491

  Dawson, M I ^a,b   Fontana, J A ^a,b  

^a BURNHAM INSTITUTE   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

3 Cl AHPC; 4 HPR; AHPC; AHPN; Apoptosis; Cell cycle arrest; Retinoid related molecule; ShetA2; ST1926

Indexed keywords

2 [3' (1 ADAMANTYL) 4' METHOXYPHENYL]BENZIMIDAZOLE 6 CARBOXYLIC ACID; 3 [3' (1 ADAMANTYL) 4' HYDROXYBIPHENYL 4 YL]ACRYLIC ACID; 3' (1 ADAMANTYL) 4',5' DIOXAMETHYLENEPHENYL; 6 [3' (1 ADAMANTYL) 4' HYDROXYPHENYL] 2 NAPHTHALENECARBOXYLIC ACID; ANTINEOPLASTIC AGENT; CINNAMIC ACID DERIVATIVE; CISPLATIN; MX 2870 1; MX 3350 1; MX 781; MX 90 1; N (2,3 DIHYDRO 2,2,4,4 TETRAMETHYL 6 BENZOTHIOPYRANYL); N' (4 NITROPHENYL)THIOUREA; O GLUCURONIDE METABOLITE; PEPTIDOMIMETIC AGENT; RETINOIC ACID; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CLINICAL TRIAL; DRUG SYNTHESIS; ENDOPLASMIC RETICULUM STRESS; HUMAN; LEUKEMIA; NONHUMAN; OVARY CANCER; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CINNAMATES; FENRETINIDE; GLUCURONATES; RECEPTORS, RETINOIC ACID; RETINOIDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77953717132     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955710791384045     Document Type: Article

References (148)

1. Alshafie, G. A.; Walker, J. R.; Curley, R. W., Jr.; Clagett-Dame, M.; Highland, M. A.; Nieves, N. J.; Stonerock, L. A.; Abou-Issa, H. Inhibition of mammary tumor growth by a novel nontoxic retinoid: Chemotherapeutic evaluation of a C-linked analog of 4-HPR-glucuronide. Anticancer Res., 2005, 25, 2391-2398.
2. Walker, J. R.; Alshafie, G.; Abou-Issa, H.; Curley, R. W., Jr. An improved synthesis of the C-linked glucuronide of N-(4-hydroxyphenyl)retinamide. Bioorg. Med. Chem. Lett., 2002, 12, 2447-2450.
3. Weiss, K. L.; Alshafie, G.; Chapman, J. S.; Mershon, S. M.; Abou-Issa, H.; Clagett-Dame, M.; Curley, R. W., Jr. An unhydrolyzable analogue of N-(4-hydroxyphenyl)retinamide. Synthesis and preliminary biological studies. Bioorg. Med. Chem. Lett., 2001, 11, 1583-1586.
4. Walker, J. R.; Alshafie, G.; Nieves, N.; Ahrens, J.; Clagett-Dame, M.; Abou-Issa, H.; Curley, R. W., Jr. Synthesis and preliminary chemotherapeutic evaluation of the fully C-linked glucuronide of N-(4-hydroxyphenyl)retinamide. Bioorg. Med. Chem., 2006, 14, 3038-3048.
5. Abou-Issa, H.; Curley, R. W., Jr.; Alshafie, G. A.; Weiss, K. L.; Clagett-Dame, M.; Chapman, J. S.; Mershon, S. M. Chemotherapeutic evaluation of 4-hydroxybenzylretinone (4-HBR), a nonhydrolyzable C-linked analog of N-(4-hydroxyphenyl) retinamide (4-HPR) against mammary carcinogenesis. Anticancer Res., 2001, 21, 3839-3844.
6. Swanson, B. N.; Newton, D. L.; Roller, P. P.; Sporn, M. B. Biotransformation and biological activity of N-(4-hydroxyphenyl) retinamide derivatives in rodents. J. Pharmacol. Exp. Ther., 1981, 219, 632-637.
7. Abou-Issa, H.; Curley, R. W., Jr.; Panigot, M. J.; Wilcox, K. A.; Webb, T. E. In vivo use of N-(4-hydroxyphenyl retinamide)-Oglucuronide as a breast cancer chemopreventive agent. Anticancer Res., 1993, 13, 1431-1436.
8. Dawson, M. I.; Hobbs, P. D. Synthesis of the D-glucuronic acid conjugates of N-(4-hydroxyphenyl)- and N-(2-hydroxyethyl)-retinamides. Carbohydr. Res., 1980, 85, 121-129.
9. Mershon, S. M.; Anding, A. L.; Chapman, J. S.; Clagett-Dame, M.; Stonerock, L. A.; Curley, R. W., Jr. Solid phase-assisted synthesis and screening of a small library of N-(4-hydroxyphenyl)retinamide (4-HPR) analogs. Bioorg. Med. Chem. Lett., 2007, 17, 836-840.
10. Su, B.; Mershon, S. M.; Stonerock, L. A.; Curley, R. W., Jr.; Brueggemeier, R. W. 4-Hydroxyphenylretinamide (4HPR) derivatives regulate aromatase activity and expression in breast cancer cells. J. Steroid Biochem. Mol. Biol., 2008, 109, 40-46.
11. Das, B. C.; Smith, M. E.; Kalpana, G. V. Design and synthesis of 4-HPR derivatives for rhabdoid tumors. Bioorg. Med. Chem. Lett., 2008, 18, 3805-3808.
12. Thatcher, J. E.; Isoherranen, N. The role of CYP26 enzymes in retinoic acid clearance. Expert Opin. Drug Metab. Toxicol., 2009, 5, 875-886.
13. Winum, J. Y.; Leydet, A.; Seman, M.; Montero, J. L. Synthesis and biological activity of glycosyl conjugates of N-(4-hydroxyphenyl) retinamide. Farmaco, 2001, 56, 319-324.
14. Curley, R. W., Jr.; Abou-Issa, H.; Panigot, M. J.; Repa, J. J.; Clagett-Dame, M.; Alshafie, G. Chemopreventive activities of Cglucuronide/glycoside analogs of retinoid-O-glucuronides against breast cancer development and growth. Anticancer Res., 1996, 16, 757-763.
15. Abou-Issa, H. M.; Alshafie, G. A.; Curley, R. W., Jr.; Wong, M. F.; Clagett-Dame, M.; Repa, J. J.; Sikri, V. Chemopreventive activity of a C-glucuronide analog of N-(4-hydroxyphenyl) retinamide-Oglucuronide against mammary tumor development and growth. Anticancer Res., 1999, 19, 999-1004.
16. Anding, A. L.; Chapman, J. S.; Barnett, D. W.; Curley, R. W., Jr.; Clagett-Dame, M. The unhydrolyzable fenretinide analogue 4- hydroxybenzylretinone induces the proapoptotic genes GADD153 (CHOP) and Bcl-2-binding component 3 (PUMA) and apoptosis that is caspase-dependent and independent of the retinoic acid receptor. Cancer Res., 2007, 67, 6270-6277.
17. Bonanni, B.; Lazzeroni, M.; Veronesi, U. Synthetic retinoid fenretinide in breast cancer chemoprevention. Expert Rev. Anticancer Ther., 2007, 7, 423-432.
18. Sheikh, M. S.; Shao, Z. M.; Li, X. S.; Ordonez, J. V.; Conley, B. A.; Wu, S.; Dawson, M. I.; Han, Q. X.; Chao, W. R.; Quick, T.; Niles, R. M.; Fontana, J. A. N-(4-Hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptorindependent pathways in human breast carcinoma. Carcinogenesis, 1995, 16, 2477-2486.
19. Fanjul, A. N.; Delia, D.; Pierotti, M. A.; Rideout, D.; Yu, J. Q.; Pfahl, M. 4-Hydroxyphenyl retinamide is a highly selective activator of retinoid receptors. J. Biol. Chem., 1996, 271, 22441-22446.
20. Lovat, P. E.; Ranalli, M.; Bernassola, F.; Tilby, M.; Malcolm, A. J.; Pearson, A. D.; Piacentini, M.; Melino, G.; Redfern, C. P. Distinct properties of fenretinide and CD437 lead to synergistic responses with chemotherapeutic reagents. Med. Pediatr. Oncol., 2000, 35, 663-668.
21. Clifford, J. L.; Menter, D. G.; Wang, M.; Lotan, R.; Lippman, S. M. Retinoid receptor-dependent and -independent effects of N-(4-hydroxyphenyl)retinamide in F9 embryonal carcinoma cells. Cancer Res., 1999, 59, 14-18.
22. Hail, N., Jr.; Lotan, R. Mitochondrial permeability transition is a central coordinating event in N-(4-hydroxyphenyl)retinamideinduced apoptosis. Cancer Epidemiol. Biomarkers Prev., 2000, 9, 1293-1301.
23. Hail, N., Jr.; Lotan, R. Mitochondrial respiration is uniquely associated with the prooxidant and apoptotic effects of N-(4-hydroxyphenyl)retinamide. J. Biol. Chem., 2001, 276, 45614-45621.
24. Asumendi, A.; Morales, M. C.; Alvarez, A.; Arechaga, J.; Pérez-Yarza, G. Implication of mitochondria-derived ROS and cardiolipin peroxidation in N-(4-hydroxyphenyl)retinamide-induced apoptosis. Br. J. Cancer, 2002, 86, 1951-1956.
25. Kim, H. J.; Chakravarti, N.; Oridate, N.; Choe, C.; Claret, F. X.; Lotan, R. N-(4-Hydroxyphenyl)retinamide-induced apoptosis triggered by reactive oxygen species is mediated by activation of MAPKs in head and neck squamous carcinoma cells. Oncogene, 2006, 25, 2785-2794.
26. Kouhara, J.; Yoshida, T.; Nakata, S.; Horinaka, M.; Wakada, M.; Ueda, Y.; Yamagishi, H.; Sakai, T. Fenretinide up-regulates DR5/TRAIL-R2 expression via the induction of the transcription factor CHOP and combined treatment with fenretinide and TRAIL induces synergistic apoptosis in colon cancer cell lines. Int. J. Oncol., 2007, 30, 679-687.
27. Lai, W. L.; Wong, N. S. ROS mediates 4HPR-induced posttranscriptional expression of the Gadd153 gene. Free Radic. Biol. Med., 2005, 38, 1585-1593.
28. Xia, Y.; Wong, N. S.; Fong, W. F.; Tideman, H. Upregulation of GADD153 expression in the apoptotic signaling of N-(4-hydroxyphenyl)retinamide (4HPR). Int. J. Cancer, 2002, 102, 7-14.
29. Schroder, M. Endoplasmic reticulum stress responses. Cell Mol. Life Sci., 2008, 65, 862-894.
30. Kadara, H.; Lacroix, L.; Lotan, D.; Lotan, R. Induction of endoplasmic reticulum stress by the pro-apoptotic retinoid N-(4-hydroxyphenyl)retinamide via a reactive oxygen species-dependent mechanism in human head and neck cancer cells. Cancer Biol. Ther., 2007, 6, 705-711.
31. Appierto, V.; Tiberio, P.; Villani, M. G.; Cavadini, E.; Formelli, F. PLAB induction in fenretinide-induced apoptosis of ovarian cancer cells occurs via a ROS-dependent mechanism involving ER stress and JNK activation. Carcinogenesis, 2009, 30, 824-831.
32. Rehman, F.; Shanmugasundaram, P.; Schrey, M. P. Fenretinide stimulates redox-sensitive ceramide production in breast cancer cells: Potential role in drug-induced cytotoxicity. Br. J. Cancer, 2004, 91, 1821-1828.
33. Vené, R.; Arena, G.; Poggi, A.; D'Arrigo, C.; Mormino, M.; Noonan, D. M.; Albini, A.; Tosetti, F. Novel cell death pathways induced by N-(4-hydroxyphenyl)retinamide: Therapeutic implications. Mol. Cancer Ther., 2007, 6, 286-298.
34. Ferrari, N.; Pfeffer, U.; Dell'Eva, R.; Ambrosini, C.; Noonan, D. M.; Albini, A. The transforming growth factor-β family members bone morphogenetic protein-2 and macrophage inhibitory cytokine-1 as mediators of the antiangiogenic activity of N-(4-hydroxyphenyl)retinamide. Clin. Cancer Res., 2005, 11, 4610-4619.
35. Formelli, F.; Cleris, L. Synthetic retinoid fenretinide is effective against a human ovarian carcinoma xenograft and potentiates cisplatin activity. Cancer Res., 1993, 53, 5374-5376.
36. Pienta, K. J.; Nguyen, N. M.; Lehr, J. E. Treatment of prostate cancer in the rat with the synthetic retinoid fenretinide. Cancer Res., 1993, 53, 224-226.
37. Chiesa, F.; Tradati, N.; Grigolato, R.; Boracchi, P.; Biganzoli, E.; Crose, N.; Cavadini, E.; Formelli, F.; Costa, L.; Giardini, R.; Zurrida, S.; Costa, A.; De Palo, G.; Veronesi, U. Randomized trial of fenretinide (4-HPR) to prevent recurrences, new localizations and carcinomas in patients operated on for oral leukoplakia: Longterm results. Int. J. Cancer, 2005, 115, 625-629.
38. Bernard, B. A.; Bernardon, J. M.; Delescluse, C.; Martin, B.; Lenoir, M. C.; Maignan, J.; Charpentier, B.; Pilgrim, W. R.; Reichert, U.; Shroot, B. Identification of synthetic retinoids with selectivity for human nuclear retinoic acid receptor γ. Biochem. Biophys. Res. Commun., 1992, 186, 977-983.
39. Chao, W. R.; Hobbs, P. D.; Jong, L.; Zhang, X. K.; Zheng, Y.; Wu, Q.; Shroot, B.; Dawson, M. I. Effects of receptor class- and subtype-selective retinoids and an apoptosis-inducing retinoid on the adherent growth of the NIH:OVCAR-3 ovarian cancer cell line in culture. Cancer Lett., 1997, 115, 1-7.
40. 1 arrest and apoptosis induced by a novel retinoid in human breast cancer cells. Oncogene, 1995, 11, 493-504.
41. Fontana, J. A. Method for treating or preventing breast cancer or leukemia using 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalenecarboxylic acid. U.S. Patent 6,211,239, April 3, 2001.
42. WAF1/CIP1 expression in human breast carcinoma cells. Cancer Res., 1996, 56, 5055-5062.
43. L expression and its downregulation by a novel retinoid in breast carcinoma cells. Exp. Cell Res., 1997, 232, 17-24.
44. Hsu, C. A.; Rishi, A. K.; Su-Li, X.; Gerald, T. M.; Dawson, M. I.; Schiffer, C.; Reichert, U.; Shroot, B.; Poirer, G. C.; Fontana, J. A. Retinoid induced apoptosis in leukemia cells through a retinoic acid nuclear receptor-independent pathway. Blood, 1997, 89, 4470-4479.
45. L fails to inhibit apoptosis mediated by a novel retinoid. Oncol. Res., 1998, 10, 313-324.
46. Liang, J. Y.; Fontana, J. A.; Rao, J. N.; Ordonez, J. V.; Dawson, M. I.; Shroot, B.; Wilber, J. F.; Feng, P. Synthetic retinoid CD437 induces S-phase arrest and apoptosis in human prostate cancer cells LNCaP and PC-3. Prostate, 1999, 38, 228-236.
47. Rishi, A. K.; Sun, R. J.; Gao, Y.; Hsu, C. K.; Gerald, T. M.; Sheikh, M. S.; Dawson, M. I.; Reichert, U.; Shroot, B.; Fornace, A. J., Jr.; Brewer, G.; Fontana, J. A. Post-transcriptional regulation of the DNA damage-inducible gadd45 gene in human breast carcinoma cells exposed to a novel retinoid CD437. Nucleic Acids Res., 1999, 27, 3111-3119.
48. Zhang, Y.; Huang, Y.; Rishi, A. K.; Sheikh, M. S.; Shroot, B.; Reichert, U.; Dawson, M.; Poirer, G.; Fontana, J. A. Activation of the p38 and JNK/SAPK mitogen-activated protein kinase pathways during apoptosis is mediated by a novel retinoid. Exp. Cell Res., 1999, 247, 233-240.
49. Farhana, L.; Dawson, M.; Rishi, A. K.; Zhang, Y.; Van Buren, E.; Trivedi, C.; Reichert, U.; Fang, G.; Kirschner, M. W.; Fontana, J. A. Cyclin B and E2F-1 expression in prostate carcinoma cells treated with the novel retinoid CD437 are regulated by the ubiquitin-mediated pathway. Cancer Res., 2002, 62, 3842-3849.
50. Rishi, A. K.; Zhang, L.; Boyanapalli, M.; Wali, A.; Mohammad, R. M.; Yu, Y.; Fontana, J. A.; Hatfield, J. S.; Dawson, M. I.; Majumdar, A. P.; Reichert, U. Identification and characterization of a cell cycle and apoptosis regulatory protein-1 as a novel mediator of apoptosis signaling by retinoid CD437. J. Biol. Chem., 2003, 278, 33422-33435.
51. Sakaue, M.; Adachi, H.; Dawson, M.; Jetten, A. M. Induction of Egr-1 expression by the retinoid AHPN in human lung carcinoma cells is dependent on activated ERK1/2. Cell Death Differ., 2001, 8, 411-424.
52. Sun, S. Y.; Yue, P.; Shroot, B.; Hong, W. K.; Lotan, R. Induction of apoptosis in human non-small cell lung carcinoma cells by the novel synthetic retinoid CD437. J. Cell Physiol., 1997, 173, 279-284.
53. Adachi, H.; Adams, A.; Hughes, F. M.; Zhang, J.; Cidlowski, J. A.; Jetten, A. M. Induction of apoptosis by the novel retinoid AHPN in human T-cell lymphoma cells involves caspase-dependent and independent pathways. Cell Death Differ., 1998, 5, 973-983.
54. Li, Y.; Lin, B.; Agadir, A.; Liu, R.; Dawson, M. I.; Reed, J. C.; Fontana, J. A.; Bost, F.; Hobbs, P. D.; Zheng, Y.; Chen, G. Q.; Shroot, B.; Mercola, D.; Zhang, X.-K. Molecular determinants of AHPN (CD437)-induced growth arrest and apoptosis in human lung cancer cell lines. Mol. Cell Biol., 1998, 18, 4719-4731.
55. Wu, S.; Zhang, D.; Donigan, A.; Dawson, M. I.; Soprano, D. R.; Soprano, K. J. Effects of conformationally restricted synthetic retinoids on ovarian tumor cell growth. J. Cell Biochem., 1998, 68, 378-388.
56. Sun, S. Y.; Kurie, J. M.; Yue, P.; Dawson, M. I.; Shroot, B.; Chandraratna, R. A. S.; Hong, W. K.; Lotan, R. Differential responses of normal, premalignant, and malignant human bronchial epithelial cells to receptor-selective retinoids. Clin. Cancer Res., 1999, 5, 431-437.
57. Meister, B.; Fink, F. M.; Hittmair, A.; Marth, C.; Widschwendter, M. Antiproliferative activity and apoptosis induced by retinoic acid receptor-γ selectively binding retinoids in neuroblastoma. Anticancer Res., 1998, 18, 1777-1786.
58. Gianni, M.; de Thé, H. In acute promyelocytic leukemia NB4 cells, the synthetic retinoid CD437 induces contemporaneously apoptosis, a caspase-3-mediated degradation of PML/RARα protein and the PML retargeting on PML-nuclear bodies. Leukemia, 1999, 13, 739-749.
59. Gonda, K.; Tsuchiya, H.; Sakabe, T.; Akechi, Y.; Ikeda, R.; Nishio, R.; Terabayashi, K.; Ishii, K.; Matsumi, Y.; Ashla, A. A.; Okamoto, H.; Takubo, K.; Matsuoka, S.; Watanabe, Y.; Hoshikawa, Y.; Kurimasa, A.; Shiota, G. Synthetic retinoid CD437 induces mitochondria-mediated apoptosis in hepatocellular carcinoma cells. Biochem. Biophys. Res. Commun., 2008, 370, 629-633.
60. Zhao, X.; Demary, K.; Wong, L.; Vaziri, C.; McKenzie, A. B.; Eberlein, T. J.; Spanjaard, R. A. Retinoic acid receptor-independent mechanism of apoptosis of melanoma cells by the retinoid CD437 (AHPN). Cell Death Differ., 2001, 8, 878-886.
61. Sun, S. Y.; Yue, P.; Chen, X.; Hong, W. K.; Lotan, R. The synthetic retinoid CD437 selectively induces apoptosis in human lung cancer cells while sparing normal human lung epithelial cells. Cancer Res., 2002, 62, 2430-2436.
62. Sun, S. Y.; Yue, P.; Chandraratna, R. A. S.; Tesfaigzi, Y.; Hong, W.-K.; Lotan, R. Dual mechanisms of action of the retinoid CD437: Nuclear retinoic acid receptor-mediated suppression of squamous differentiation and receptor-independent induction of apoptosis in UMSCC22B human head and neck squamous cell carcinoma cells. Mol. Pharmacol., 2000, 58, 508-514.
63. Sun, S. Y.; Yue, P.; Mao, L.; Dawson, M. I.; Shroot, B.; Lamph, W. W.; Heyman, R. A.; Chandraratna, R. A. S.; Shudo, K.; Hong, W. K.; Lotan, R. Identification of receptor-selective retinoids that are potent inhibitors of the growth of human head and neck squamous cell carcinoma cells. Clin. Cancer Res., 2000, 6, 1563-1573.
64. Zang, Y.; Beard, R. L.; Chandraratna, R. A. S.; Kang, J. X. Evidence of a lysosomal pathway for apoptosis induced by the synthetic retinoid CD437 in human leukemia HL-60 cells. Cell Death Differ., 2001, 8, 477-485.
65. Pfahl, M.; Piedrafita, F. J. Retinoid targets for apoptosis induction. Oncogene, 2003, 22, 9058-9062.
66. Lu, X. P.; Fanjul, A.; Picard, N.; Pfahl, M.; Rungta, D.; Nared-Hood, K.; Carter, B.; Piedrafita, J.; Tang, S.; Fabbrizio, E. Novel retinoid-related molecules as apoptosis inducers and effective inhibitors of human lung cancer cells in vivo. Nat. Med., 1997, 3, 686-690.
67. Pfahl, M. Retinoid related molecules: New promises against lung and breast cancer. Expert Opin. Investig. Drugs 1998, 7, 601-606.
68. Yarovoi, S. V.; Lu, X. P.; Picard, N.; Rungta, D.; Rideout, D.; Pfahl, M. Selective activation of an apoptotic retinoid precursor in macrophage cell lines. J. Biol. Chem., 1998, 273, 20852-20859.
69. Fanjul, A. N.; Piedrafita, F. J.; Al-Shamma, H.; Pfahl, M. Apoptosis induction and potent antiestrogen receptor-negative breast cancer activity in vivo by a retinoid antagonist. Cancer Res., 1998, 58, 4607-4610.
70. Lu, X. P.; Fanjul, A.; Picard, N.; Shroot, B.; Pfahl, M. A selective retinoid with high activity against an androgen-resistant prostate cancer cell type. Int. J. Cancer, 1999, 80, 272-278.
71. Cincinelli, R.; Dallavalle, S.; Merlini, L.; Penco, S.; Pisano, C.; Carminati, P.; Giannini, G.; Vesci, L.; Gaetano, C.; Illy, B.; Zuco, V.; Supino, R.; Zunino, F. A novel atypical retinoid endowed with proapoptotic and antitumor activity. J. Med. Chem., 2003, 46, 909-912.
72. Di Francesco, A. M.; Meco, D.; Torella, A. R.; Barone, G.; D'Incalci, M.; Pisano, C.; Carminati, P.; Riccardi, R. The novel atypical retinoid ST1926 is active in ATRA resistant neuroblastoma cells acting by a different mechanism. Biochem. Pharmacol., 2007, 73, 643-655.
73. Zuco, V.; Zanchi, C.; Lanzi, C.; Beretta, G. L.; Supino, R.; Pisano, C.; Barbarino, M.; Zanier, R.; Bucci, F.; Aulicino, C.; Carminati, P.; Zunino, F. Development of resistance to the atypical retinoid, ST1926, in the lung carcinoma cell line H460 is associated with reduced formation of DNA strand breaks and a defective DNA damage response. Neoplasia, 2005, 7, 667-677.
74. Garattini, E.; Gianni, M.; Terao, M. Retinoid related molecules an emerging class of apoptotic agents with promising therapeutic potential in oncology: Pharmacological activity and mechanisms of action. Curr. Pharm. Des., 2004, 10, 433-448.
75. Garattini, E.; Parrella, E.; Diomede, L.; Gianni, M.; Kalac, Y.; Merlini, L.; Simoni, D.; Zanier, R.; Ferrara, F. F.; Chiarucci, I.; Carminati, P.; Terao, M.; Pisano, C. ST1926, a novel and orally active retinoid-related molecule inducing apoptosis in myeloid leukemia cells: Modulation of intracellular calcium homeostasis. Blood, 2004, 103, 194-207.
76. Parrella, E.; Gianni, M.; Fratelli, M.; Barzago, M. M.; Raska, I., Jr.; Diomede, L.; Kurosaki, M.; Pisano, C.; Carminati, P.; Merlini, L.; Dallavalle, S.; Tavecchio, M.; Rochette-Egly, C.; Terao, M.; Garattini, E. Antitumor activity of the retinoid-related molecules (E)-3-(4́-hydroxy-3́-adamantylbiphenyl-4-yl)acrylic acid (ST1926) and 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalenecarboxylic acid (CD437) in F9 teratocarcinoma: Role of retinoic acid receptor γ and retinoid-independent pathways. Mol. Pharmacol., 2006, 70, 909-924.
77. Valli, C.; Paroni, G.; Di Francesco, A. M.; Riccardi, R.; Tavecchio, M.; Erba, E.; Boldetti, A.; Gianni, M.; Fratelli, M.; Pisano, C.; Merlini, L.; Antoccia, A.; Cenciarelli, C.; Terao, M.; Garattini, E. Atypical retinoids ST1926 and CD437 are S-phase-specific agents causing DNA double-strand breaks: Significance for the cytotoxic and antiproliferative activity. Mol. Cancer Ther., 2008, 7, 2941-2954.
78. Pisano, C.; Vesci, L.; Fodera, R.; Ferrara, F. F.; Rossi, C.; De Cesare, M.; Zuco, V.; Pratesi, G.; Supino, R.; Zunino, F. Antitumor activity of the combination of synthetic retinoid ST1926 and cisplatin in ovarian carcinoma models. Ann. Oncol., 2007, 18, 1500-1505.
79. Zuco, V.; Benedetti, V.; De Cesare, M.; Zunino, F. Sensitization of ovarian carcinoma cells to the atypical retinoid ST1926 by the histone deacetylase inhibitor, RC307: Enhanced DNA damage response. Int. J. Cancer, 2010, 126, 1246-1255.
80. Sala, F.; Zucchetti, M.; Bagnati, R.; D'Incalci, M.; Pace, S.; Capocasa, F.; Marangon, E. Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of ST1926, a novel oral antitumor agent, adamantly retinoid derivative, in plasma of patients in a phase I study. J. Chromatogr. B, Analyt. Technol. Biomed. Life Sci., 2009, 877, 3118-3126.
81. Fontana, J. A.; Dawson, M. I.; Leid, M.; Rishi, A. K.; Zhang, Y.; Hsu, C. A.; Lu, J. S.; Peterson, V. J.; Jong, L.; Hobbs, P.; Chao, W. R.; Shroot, B.; Reichert, U. Identification of a unique binding protein specific for a novel retinoid inducing cellular apoptosis. Int. J. Cancer, 2000, 86, 474-479.
82. Farhana, L.; Dawson, M. I.; Leid, M.; Wang, L.; Moore, D. D.; Liu, G.; Xia, Z.; Fontana, J. A. Adamantyl-substituted retinoidrelated molecules bind small heterodimer partner and modulate the Sin3A repressor. Cancer Res., 2007, 67, 318-325.
83. Farhana, L.; Dawson, M. I.; Dannenberg, J. H.; Xu, L.; Fontana, J. A. SHP and Sin3A expression are essential for adamantylsubstituted retinoid-related molecule-mediated nuclear factor-KB activation, c-Fos/c-Jun expression, and cellular apoptosis. Mol. Cancer Ther., 2009, 8, 1625-1635.
84. Dawson, M. I.; Hobbs, P. D.; Peterson, V. J.; Leid, M.; Lange, C. W.; Feng, K. C.; Chen, G.; Gu, J.; Li, H.; Kolluri, S. K.; Zhang, X.; Zhang, Y.; Fontana, J. A. Apoptosis induction in cancer cells by a novel analogue of 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2- naphthalenecarboxylic acid lacking retinoid receptor transcriptional activation activity. Cancer Res., 2001, 61, 4723-4730.
85. Zhang, Y.; Dawson M. I.; Mohammad R.; Rishi A. K.; Farhana L.; Feng K. C.; Leid M.; Peterson V.; Zhang X.-K.; Edelstein M.; Eilander D.; Biggar S.; Wall N.; Reichert U.; Fontana J. A. Induction of apoptosis of human B-CLL and ALL cells by a novel retinoid and its nonretinoidal analog. Blood, 2002, 100, 2917-2925.
86. Zhang, Y.; Dawson, M. I.; Ning, Y.; Polin, L.; Parchment, R. E.; Corbett, T.; Mohamed, A. N.; Feng, K.-C.; Farhana, L.; Rishi, A. K.; Hogge, D.; Leid, M.; Peterson, V. J.; Zhang, X.-K.; Mohammad, R.; Lu, J. S.; Willman, C.; VanBuren, E.; Biggar, S.; Edelstein, M.; Eilender, D.; Fontana, J. A. Induction of apoptosis in retinoid-refractory acute myelogenous leukemia by a novel AHPN analog. Blood, 2003, 102, 3743-3752.
87. Farhana, L.; Dawson, M. I.; Huang, Y.; Zhang, Y.; Rishi, A. K.; Reddy, K. B.; Freeman, R. S.; Fontana, J. A. Apoptosis signaling by the novel compound 3-Cl-AHPC involves increased EGFR proteolysis and accompanying decreased phosphatidylinositol 3-kinase and AKT kinase activities. Oncogene, 2004, 23, 1874-1884.
88. Dawson, M. I.; Fontana, J.A.; Zhang, X-.K.; Leid, M., Jong, L., Hobbs, P.D. Induction of apoptosis in cancer cells. U.S. Patent 7,053,071, May 30, 2006.
89. Pisano, C.; Vesci, L. Use of adamantyl methoxydiphenylpropenoic acid for the treatment of acne. U.S. Patent 7,635,719, December 22, 2009.
90. Dawson, M. I.; Xia, Z.; Liu, G.; Ye, M.; Fontana, J. A.; Farhana, L.; Patel, B. B.; Arumugarajah, S.; Bhuiyan, M.; Zhang, X.-K.; Han, Y. H.; Stallcup, W. B.; Fukushi, J.; Mustelin, T.; Tautz, L.; Su, Y.; Harris, D. L.; Waleh, N.; Hobbs, P. D.; Jong, L.; Chao, W.-R.; Schiff, L. J.; Sani, B. P. An adamantyl-substituted retinoidderived molecule that inhibits cancer cell growth and angiogenesis by inducing apoptosis and binds to small heterodimer partner nuclear receptor: Effects of modifying its carboxylate group on apoptosis, proliferation, and protein-tyrosine phosphatase activity. J. Med. Chem., 2007, 50, 2622-2639.
91. Dawson, M. I.; Xia, Z.; Jiang, T.; Ye, M.; Fontana, J. A.; Farhana, L.; Patel, B.; Xue, L. P.; Bhuiyan, M.; Pellicciari, R.; Macchiarulo, A.; Nuti, R.; Zhang, X.-K.; Han, Y. H.; Tautz, L.; Hobbs, P. D.; Jong, L.; Waleh, N.; Chao, W.-R.; Feng, G. S.; Pang, Y.; Su, Y. Adamantyl-substituted retinoid-derived molecules that interact with the orphan nuclear receptor small heterodimer partner: Effects of replacing the 1-adamantyl or hydroxyl group on inhibition of cancer cell growth, induction of cancer cell apoptosis, and inhibition of SRC homology 2 domain-containing protein tyrosine phosphatase-2 activity. J. Med. Chem., 2008, 51, 5650-5662.
92. Charpentier, B.; Bernardon, J. M.; Eustache, J.; Millois, C.; Martin, B.; Michel, S.; Shroot, B. Synthesis, structure-affinity relationships, and biological activities of ligands binding to retinoic acid receptor subtypes. J. Med. Chem., 1995, 38, 4993-5006.
93. Pérez-Rodríguez, S.; Ortiz, M. A.; Pereira, R.; Rodriguez-Barrios, F.; de Lera, A. R.; Piedrafita, F. J. Highly twisted adamantyl arotinoids: Synthesis, antiproliferative effects and RXR transactivation profiles. Eur. J. Med. Chem., 2009, 44, 2434-2446.
94. Lorenzo, P.; Alvarez, R.; Ortiz, M. A.; Alvarez, S.; Piedrafita, F. J.; de Lera, A. R. Inhibition of IKB kinase-β and anticancer activities of novel chalcone adamantyl arotinoids. J. Med. Chem., 2008, 51, 5431-5440.
95. Macchiarulo, A.; Rizzo, G.; Costantino, G.; Fiorucci, S.; Pellicciari, R. Unveiling hidden features of orphan nuclear receptors: The case of the small heterodimer partner (SHP). J. Mol. Graph Model., 2006, 24, 362-372.
96. Evans, R. M.; Ong, E.; Segui, P.S.; Thompson, C.C.; Umesomo, K.; Giguere, V. Retinoic acid receptor method. U.S. Patent 4,981,784, January 1, 1991.
97. Evans, R. M.; Heyman, R.A.; Berger, C.S.; Stein, R.B. Use of selective ligands for treatment of disease states responsive to steroid or steroid-like hormones. U.S. Patent 6,096,787, August 1, 2000.
98. Dawson, M. I.; Harris, D. L.; Liu, G.; Hobbs, P. D.; Lange, C. W.; Jong, L.; Bruey-Sedano, N.; James, S. Y.; Zhang, X.-K.; Peterson, V. J.; Leid, M.; Farhana, L.; Rishi, A. K.; Fontana, J. A. Antagonist analogue of 6-[3'-(1-adamantyl)-4'-hydroxyphenyl]-2-naphthalenecarboxylic acid (AHPN) family of apoptosis inducers that effectively blocks AHPN-induced apoptosis but not cell-cycle arrest. J. Med. Chem., 2004, 47, 3518-3536.
99. Cincinelli, R.; Dallavalle, S.; Nannei, R.; Merlini, L.; Penco, S.; Giannini, G.; Pisano, C.; Vesci, L.; Ferrara, F. F.; Zuco, V.; Zanchi, C.; Zunino, F. Synthesis and structure-activity relationships of new antiproliferative and proapoptotic retinoid-related biphenyl-4-ylacrylic acids. Bioorg. Med. Chem., 2007, 15, 4863-4875.
100. Kagechika, H.; Kawachi, E.; Hashimoto, Y.; Shudo, K. Retinobenzoic acids. 2. Structure-activity relationships of chalcone-4-carboxylic acids and flavone-4'-carboxylic acids. J. Med. Chem., 1989, 32, 834-840.
101. Lopez-Hernandez, F. J.; Ortiz, M. A.; Bayon, Y.; Piedrafita, F. J. Z-FA-fmk inhibits effector caspases but not initiator caspases 8 and 10, and demonstrates that novel anticancer retinoid-related molecules induce apoptosis via the intrinsic pathway. Mol. Cancer Ther., 2003, 2, 255-263.
102. Adachi, H.; Preston, G.; Harvat, B.; Dawson, M. I.; Jetten, A. M. Inhibition of cell proliferation and induction of apoptosis by the retinoid AHPN in human lung carcinoma cells. Am. J. Respir. Cell. Mol. Biol., 1998, 18, 323-333.
103. Holmes, W. F.; Dawson, M. I.; Soprano, R. D.; Soprano, K. J. Induction of apoptosis in ovarian carcinoma cells by AHPN/CD437 is mediated by retinoic acid receptors. J. Cell Physiol., 2000, 185, 61-67.
104. Hsu, S. L.; Yin, S. C.; Liu, M. C.; Reichert, U.; Ho, W. L. Involvement of cyclin-dependent kinase activities in CD437-induced apoptosis. Exp. Cell Res., 1999, 252, 332-341.
105. Costa, S. L.; Paillaud, E.; Fages, C.; Rochette-Egly, C.; Plassat, J. L.; Jouault, H.; Perzelova, A.; Tardy, M. Effects of a novel synthetic retinoid on malignant glioma in vitro: Inhibition of cell proliferation, induction of apoptosis and differentiation. Eur. J. Cancer, 2001, 37, 520-530.
106. Zhang, Y.; Rishi, A. K.; Dawson, M. I.; Tschang, R.; Farhana, L.; Boyanapalli, M.; Reichert, U.; Shroot, B.; Van Buren, E. C.; Fontana, J. A. S-phase arrest and apoptosis induced in normal mammary epithelial cells by a novel retinoid. Cancer Res., 2000, 60, 2025-2032.
107. Nicholson, D. W.; Ali, A.; Thornberry, N. A.; Vaillancourt, J. P.; Ding, C. K.; Gallant, M.; Gareau, Y.; Griffin, P. R.; Labelle, M.; Lazebnik, Y. A.; Munday, N. A.; Raju, S. M.; Smulson, M. E.; Yamin, T.-T.; Yu, V. L.; Miller, D. K. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature, 1995, 376, 37-43.
108. Fernandes-Alnemri, T.; Litwack, G.; Alnemri, E. S. CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1β-converting enzyme. J. Biol. Chem., 1994, 269, 30761-30764.
109. Kumar, S.; Lavin, M. F. The ICE family of cysteine proteases as effectors of cell death. Cell Death Differ., 1996, 3, 255-267.
110. Ortiz, M. A.; Lopez-Hernandez, F. J.; Bayon, Y.; Pfahl, M.; Piedrafita, F. J. Retinoid-related molecules induce cytochrome c release and apoptosis through activation of c-Jun NH2-terminal kinase/p38 mitogen-activated protein kinases. Cancer Res., 2001, 61, 8504-8512.
111. Holmes, W. F.; Soprano, D. R.; Soprano, K. J. Early events in the induction of apoptosis in ovarian carcinoma cells by CD437: Activation of the p38 MAP kinase signal pathway. Oncogene, 2003, 22, 6377-6386.
112. Boisvieux-Ulrich, E.; Sourdeval, M.; Marano, F. CD437, a synthetic retinoid, induces apoptosis in human respiratory epithelial cells via caspase-independent mitochondrial and caspase-8-dependent pathways both up-regulated by JNK signaling pathway. Exp. Cell Res., 2005, 307, 76-90.
113. Lin, B.; Kolluri, S. K.; Lin, F.; Liu, W.; Han, Y. H.; Cao, X.; Dawson, M. I.; Reed, J. C.; Zhang, X.-K. Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3. Cell, 2004, 116, 527-540.
114. Liang, B.; Song, X.; Liu, G.; Li, R.; Xie, J.; Xiao, L.; Du, M.; Zhang, Q.; Xu, X.; Gan, X.; Huang, D. Involvement of TR3/Nur77 translocation to the endoplasmic reticulum in ER stress-induced apoptosis. Exp. Cell Res., 2007, 313, 2833-2844.
115. Beg, A. A.; Baltimore, D. An essential role for NF-KB in preventing TNF-α-induced cell death. Science, 1996, 274, 782-784.
116. Beg, A. A.; Sha, W. C.; Bronson, R. T.; Ghosh, S.; Baltimore, D. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-KB. Nature, 1995, 376, 167-170.
117. Van Antwerp, D. J.; Martin, S. J.; Kafri, T.; Green, D. R.; Verma, I. M. Suppression of TNF- α -induced apoptosis by NF-KB. Science, 1996, 274, 787-789.
118. Turco, M. C.; Romano, M. F.; Petrella, A.; Bisogni, R.; Tassone, P.; Venuta, S. NF-KB/Rel-mediated regulation of apoptosis in hematologic malignancies and normal hematopoietic progenitors. Leukemia, 2004, 18, 11-17.
119. Abbadie, C.; Kabrun, N.; Bouali, F.; Smardova, J.; Stéhelin, D.; Vandenbunder, B.; Enrietto, P. J. High levels of c-rel expression are associated with programmed cell death in the developing avian embryo and in bone marrow cells in vitro. Cell, 1993, 75, 899-912.
120. Kitajima, I.; Soejima, Y.; Takasaki, I.; Beppu, H.; Tokioka, T.; Maruyama, I. Ceramide-induced nuclear translocation of NF-KB is a potential mediator of the apoptotic response to TNF- α in murine clonal osteoblasts. Bone, 1996, 19, 263-270.
121. Hunot, S.; Brugg, B.; Ricard, D.; Michel, P. P.; Muriel, M. P.; Ruberg, M.; Faucheux, B. A.; Agid, Y.; Hirsch, E. C. Nuclear translocation of NF-KB is increased in dopaminergic neurons of patients with Parkinson disease. Proc. Natl. Acad. Sci. U.S.A., 1997, 94, 7531-7536.
122. Panet, H.; Barzilai, A.; Daily, D.; Melamed, E.; Offen, D. Activation of nuclear transcription factor kappa B (NF-KB) is essential for dopamine-induced apoptosis in PC12 cells. J. Neurochem., 2001, 77, 391-398.
123. Muller, I.; Pfister, S. M.; Grohs, U.; Zweigner, J.; Handgretinger, R.; Niethammer, D.; Bruchelt, G. Receptor activator of nuclear factor KB ligand plays a nonredundant role in doxorubicin-induced apoptosis. Cancer Res., 2003, 63, 1772-1775.
124. Huang, Y.; Fang, Y.; Wu, J.; Dziadyk, J. M.; Zhu, X.; Sui, M.; Fan, W. Regulation of Vinca alkaloid-induced apoptosis by NF-KB/IKB pathway in human tumor cells. Mol. Cancer Ther., 2004, 3, 271-277.
125. Farhana, L.; Dawson, M. I.; Fontana, J. A. Apoptosis induction by a novel retinoid-related molecule requires nuclear factor-KB activation. Cancer Res., 2005, 65, 4909-4917.
126. Jin, F.; Liu, X.; Zhou, Z.; Yue, P.; Lotan, R.; Khuri, F. R.; Chung, L. W.; Sun, S. Y. Activation of nuclear factor-KB contributes to induction of death receptors and apoptosis by the synthetic retinoid CD437 in DU145 human prostate cancer cells. Cancer Res., 2005, 65, 6354-6363.
127. Schadendorf, D.; Kern, M. A.; Artuc, M.; Pahl, H. L.; Rosenbach, T.; Fichtner, I.; Nurnberg, W.; Stuting, S.; von Stebut, E.; Worm, M.; Makki, A.; Jurgovsky, K.; Kolde, G.; Henz, B. M. Treatment of melanoma cells with the synthetic retinoid CD437 induces apoptosis via activation of AP-1 in vitro, and causes growth inhibition in xenografts in vivo. J. Cell Biol., 1996, 135, 1889-1898.
128. Langdon, S. P.; Rabiasz, G. J.; Ritchie, A. A.; Reichert, U.; Buchan, P.; Miller, W. R.; Smyth, J. F. Growth-inhibitory effects of the synthetic retinoid CD437 against ovarian carcinoma models in vitro and in vivo. Cancer Chemother. Pharmacol., 1998, 42, 429-432.
129. Liu, T. J.; Koul, D.; LaFortune, T.; Tiao, N.; Shen, R. J.; Maira, S. M.; Garcia-Echevrria, C.; Yung, W. K. NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol. Cancer Ther., 2009, 8, 2204-2210.
130. Liu, S.; Brown, C. W.; Berlin, K. D.; Dhar, A.; Guruswamy, S.; Brown, D.; Gardner, G. J.; Birrer, M. J.; Benbrook, D. M. Synthesis of flexible sulfur-containing heteroarotinoids that induce apoptosis and reactive oxygen species with discrimination between malignant and benign cells. J. Med. Chem., 2004, 47, 999-1007.
131. Sousa, M. O.; Miranda, T. L.; Costa, E. B.; Bittar, E. R.; Santoro, M. M.; Figueiredo, A. F. Linear competitive inhibition of human tissue kallikrein by 4-aminobenzamidine and benzamidine and linear mixed inhibition by 4-nitroaniline and aniline. Braz. J. Med. Biol. Res., 2001, 34, 35-44.
132. Assmann, N.; Emmrich, M.; Kampf, G.; Kaiser, M. Genotoxic activity of important nitrobenzenes and nitroanilines in the Ames test and their structure-activity relationship. Mutat. Res., 1997, 395, 139-144.
133. Nair, R. S.; Auletta, C. S.; Schroeder, R. E.; Johannsen, F. R. Chronic toxicity, oncogenic potential, and reproductive toxicity of p-nitroaniline in rats. Fundam. Appl. Toxicol., 1990, 15, 607-621.
134. Spruce, L. W.; Gale, J. B.; Berlin, K. D.; Verma, A. K.; Breitman, T. R.; Ji, X. H.; van der Helm, D. Novel heteroarotinoids: Synthesis and biological activity. J. Med. Chem., 1991, 34, 430-439.
135. Zacheis, D.; Dhar, A.; Lu, S.; Madler, M. M.; Klucik, J.; Brown, C. W.; Liu, S.; Clement, F.; Subramanian, S.; Weerasekare, G. M.; Berlin, K. D.; Gold, M. A.; Houck, J. R., Jr.; Fountain, K. R.; Benbrook, D. M. Heteroarotinoids inhibit head and neck cancer cell lines in vitro and in vivo through both RAR and RXR retinoic acid receptors. J. Med. Chem., 1999, 42, 4434-4445.
136. Dhar, A.; Liu, S.; Klucik, J.; Berlin, K. D.; Madler, M. M.; Lu, S.; Ivey, R. T.; Zacheis, D.; Brown, C. W.; Nelson, E. C.; Birckbichler, P. J.; Benbrook, D. M. Synthesis, structure-activity relationships, and RARK-ligand interactions of nitrogen heteroarotinoids. J. Med. Chem., 1999, 42, 3602-3614.
137. Dawson, M. I.; Hobbs, P. D.; Derdzinski, K.; Chan, R. L.; Gruber, J.; Chao, W. R.; Smith, S.; Thies, R. W.; Schiff, L. J. Conformationally restricted retinoids. J. Med. Chem., 1984, 27, 1516-1531.
138. Waugh, K. M.; Berlin, K. D.; Ford, W. T.; Holt, E. M.; Carrol, J. P.; Schomber, P. R.; Thompson, M. D.; Schiff, L. J. Synthesis and characterization of selected heteroarotinoids. Pharmacological activity as assessed in vitamin A deficient hamster tracheal organ cultures. Single-crystal X-ray diffraction analysis of 4,4-dimethylthiochroman-6-yl methyl ketone 1,1-dioxide and ethyl (E)-p-[2-(4,4-dimethylthiochroman-6-yl)propenyl]benzoate. J. Med. Chem., 1985, 28, 116-124.
139. Benbrook, D. M.; Kamelle, S. A.; Guruswamy, S. B.; Lightfoot, S. A.; Rutledge, T. L.; Gould, N. S.; Hannafon, B. N.; Dunn, S. T.; Berlin, K. D. Flexible heteroarotinoids (Flex-Hets) exhibit improved therapeutic ratios as anticancer agents over retinoic acid receptor agonists. Invest. New Drugs, 2005, 23, 417-428.
140. Chun, K.-H.; Benbrook, D. M.; Berlin, K. D.; Hong, W. K.; Lotan, R. The synthetic heteroarotinoid SHetA2 induces apoptosis in squamous carcinoma cells through a receptor-independent and mitochondria-dependent pathway. Cancer Res., 2003, 63, 3826-3832.
141. Lin, Y. D.; Chen, S.; Yue, P.; Zou, W.; Benbrook, D. M.; Liu, S.; Le, T. C.; Berlin, K. D.; Khuri, F. R.; Sun, S. Y. CAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction is a major component of SHetA2-induced apoptosis in lung cancer cells. Cancer Res., 2008, 68, 5335-5344.
142. Myers, T.; Chengedza, S.; Lightfoot, S.; Pan, Y.; Dedmond, D.; Cole, L.; Tang, Y.; Benbrook, D. M. Flexible heteroarotinoid (Flex-Het) SHetA2 inhibits angiogenesis in vitro and in vivo. Invest. New Drugs, 2009, 27, 304-318.
143. Zhang, Y.; Hua, Y.; Benbrook, D. M.; Covey, J. M.; Dai, G.; Liu, Z.; Chan, K. K. High performance liquid chromatographic analysis and preclinical pharmacokinetics of the heteroarotinoid antitumor agent, SHetA2. Cancer Chemother. Pharmacol., 2006, 58, 561-569.
144. Liu, T.; Hannafon, B.; Gill, L.; Kelly, W.; Benbrook, D. Flex-Hets differentially induce apoptosis in cancer over normal cells by directly targeting mitochondria. Mol. Cancer Ther., 2007, 6, 1814-1822.
145. Bhatnagar, R.; Abou-Issa, H.; Curley, R. W., Jr.; Koolemans-Beynen, A.; Moeschberger, M. L.; Webb, T. E. Growth suppression of human breast carcinoma cells in culture by N-(4-hydroxyphenyl)retinamide and its glucuronide and through synergism with glucarate. Biochem. Pharmacol., 1991, 41, 1471-1477.
146. Abou-Issa, H.; Curley, R. W., Jr.; Panigot, M. J.; Tanagho, S. N.; Sidhu, B. S.; Alshafie, G. A. Chemotherapeutic evaluation of N-(4-hydroxyphenyl) retinamide-O-glucuronide in the rat mammary tumor model. Anticancer Res., 1997, 17, 3335-3339.
147. Liu, T. J.; Koul, D.; LaFortune, T.; Tiao, N.; Shen, R. J.; Maira, S. M.; Garcia-Echevrria, C.; Yung, W. K. NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol. Cancer Ther., 2009, 8, 2204-2210.
148. Le, T. C.; Berlin, K. D.; Benson, S. D.; Eastman, M. A.; Bell-Eunice, G.; Nelson, A. C.; Benbrook, D. M. Heteroarotinoids with anticancer activity against ovarian cancer cells. Open Med. Chem. J., 2007, 1, 11-23.